Atlas Trials

Study of CB-183,315 in Participants With Clostridium Difficile Infection

Clinical trial NCT01085591 · COMPLETED

Trial details

NCT number
NCT01085591
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Clostridium Difficile InfectionDiarrhea
Start date
2010-04-01
Primary completion
2011-04-13
Enrollment
210

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.